Skip to main content
Contact Us
Subscribe
E-Edition
82°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pharvaris N.V.
(NQ:
PHVS
)
18.32
-0.11 (-0.60%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pharvaris N.V.
< Previous
1
2
Next >
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
September 05, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024
September 05, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Presents Data at the Bradykinin Symposium 2024
September 05, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium
August 28, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Announces Annual Meeting of Shareholders
June 11, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
June 04, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
May 13, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
April 10, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
April 10, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
April 04, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
March 18, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
March 06, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
March 05, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
February 22, 2024
Antagonism of the bradykinin B2 receptor via treatment with deucrictibant resulted in statistically significant reduction in rate of HAE attacks
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Announces Extraordinary Meeting of Shareholders
February 16, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris to Present at the WSAAI Annual Meeting 2024
January 26, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
January 22, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities
January 05, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023
December 08, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants
December 06, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks
December 06, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris to Present at the GA²LEN UCARE Conference 2023
November 30, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer
November 15, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting
November 09, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update
November 02, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting
October 30, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris To Present at the APAAACI 2023 International Conference
October 13, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris To Present at the CIIC Fall 2023 Conference
October 04, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.